Skip to content
  • Instagram
  • YouTube
  • X

PharmaBR.News

  • About Us

Semaglutide

  • Brazil seen as priority market for Novo Nordisk’s oral Wegovy
    24 de March de 2026

    Brazil seen as priority market for Novo Nordisk’s oral Wegovy

    pietrorubin
  • Brazil’s ANVISA updates status of semaglutide registration requests
    21 de March de 2026

    Brazil’s ANVISA updates status of semaglutide registration requests

    pietrorubin
  • Brazil’s Ozempic generics expected to move billions in 2026
    16 de March de 2026

    Brazil’s Ozempic generics expected to move billions in 2026

    pietrorubin
  • Brazil braces for generic weight-loss pens as Ozempic patent expires
    11 de January de 2026

    Brazil braces for generic weight-loss pens as Ozempic patent expires

    pietrorubin
  • STJ postpones ruling on semaglutide patent dispute, delaying entry of Ozempic generics in Brazil
    10 de December de 2025

    STJ postpones ruling on semaglutide patent dispute, delaying entry of Ozempic generics in Brazil

    pietrorubin
  • Novo Nordisk’s billion-real investment positions Brazil as hub for next-gen semaglutide production
    2 de December de 2025

    Novo Nordisk’s billion-real investment positions Brazil as hub for next-gen semaglutide production

    pietrorubin
  • Novo Nordisk seeks approval for higher-dose Wegovy formulation in Brazil
    27 de November de 2025

    Novo Nordisk seeks approval for higher-dose Wegovy formulation in Brazil

    pietrorubin
  • Brazil warns of rising counterfeit risks as high-value medicines top falsification list
    20 de November de 2025

    Brazil warns of rising counterfeit risks as high-value medicines top falsification list

    pietrorubin
  • Brazil’s Anvisa steps up response to counterfeit semaglutide and unregistered anabolic drugs
    29 de October de 2025

    Brazil’s Anvisa steps up response to counterfeit semaglutide and unregistered anabolic drugs

    pharmabrnews
  • Judicial actions for Ozempic concentrate on Brazil’s SUS amid high cost and patent barriers
    25 de October de 2025

    Judicial actions for Ozempic concentrate on Brazil’s SUS amid high cost and patent barriers

    pietrorubin

Categories

Reviews.

News.

Guides.

Deals.

Videos.

Reader Poll.

Features.

Staff Picks.

Game Culture.

Podcast.

At PharmaBR.News, we highlight key developments in Brazil’s pharmaceutical and health policy landscape.

Get our free weekly briefing straight to your inbox.

  • Instagram
  • YouTube
  • X
  • About Us

Designed with WordPress

Loading Comments...